### Pfizer's 2026 Profit Forecast: A Response to Declining COVID Product Sales Pfizer has recently announced a forecast for its 2026 profits that falls below Wall Street expectations, primarily due to anticipated declines in sales of its COVID-19 products. The pharmaceutical giant is projecting adjusted earnings per share between $2.80 and $3.00, which is lower than analysts' expectations of $3.05. This forecast has resulted in a notable drop in Pfizer's stock price, reflecting investor concerns about the company's future revenue streams as the pandemic's impact wanes and competition increases in the pharmaceutical market. Additionally, Pfizer is facing challenges from the loss of exclusivity on several drugs, further complicating its financial outlook [https://finance.yahoo.com/news/pfizer-forecasts-2026-profit-below-115431728.html, https://www.bnnbloomberg.ca/business/2025/12/16/pfizer-forecasts-2026-profit-below-expectations-on-lower-covid-product-sales]. ### Breakdown of Pfizer's 2026 Profit Forecast 1. **Profit Projections**: Pfizer's adjusted earnings per share for 2026 are estimated to be between $2.80 and $3.00, which is below the consensus estimate of $3.05 from analysts [https://finance.yahoo.com/news/pfizer-expects-decline-covid-19-121600819.html]. 2. **Impact of COVID Product Sales**: The company anticipates a significant decline in demand for its COVID-19 products, which has been a major revenue driver during the pandemic [https://www.businesstimes.com.sg/companies-markets/pfizer-forecasts-2026-profit-below-expectations-lower-covid-product-sales]. 3. **Cost-Cutting Measures**: In response to these challenges, Pfizer is implementing a $7.7 billion cost-cutting strategy aimed at mitigating the financial impact of reduced COVID sales and the impending loss of exclusivity on certain drugs [https://www.pharmaceutical-technology.com/news/pfizer-fy-2025-2026-profit-forecast-guidance]. 4. **Future Investments**: Despite the current challenges, Pfizer is also focusing on expanding its portfolio, particularly in the cardiometabolic space, as it seeks to enter the obesity market [https://www.pharmaceutical-technology.com/news/pfizer-fy-2025-2026-profit-forecast-guidance]. ### Supporting Evidence and Data - **Earnings Per Share**: Projected adjusted earnings per share for 2026: **$2.80 - $3.00**. - **Analyst Expectations**: Consensus estimate from analysts: **$3.05**. - **Stock Price Reaction**: Pfizer's shares fell by **1.6%** in premarket trading following the announcement [https://finance.yahoo.com/news/pfizer-forecasts-2026-profit-below-115431728.html]. - **Cost-Cutting Strategy**: Pfizer's planned cost reductions amount to **$7.7 billion** [https://www.pharmaceutical-technology.com/news/pfizer-fy-2025-2026-profit-forecast-guidance]. ### Conclusion: Navigating a Challenging Landscape In summary, **Pfizer's forecast for 2026 reflects significant challenges** stemming from declining COVID-19 product sales and the loss of exclusivity on key drugs. The company is taking proactive steps to address these issues through cost-cutting measures and strategic investments in new therapeutic areas. 1. **Profit Forecast**: Adjusted earnings per share projected at **$2.80 - $3.00**. 2. **Market Reaction**: Stock price decline of **1.6%** indicates investor concern. 3. **Strategic Response**: Implementation of a **$7.7 billion** cost-cutting strategy. 4. **Future Focus**: Investment in the **cardiometabolic pipeline** to diversify revenue sources. As Pfizer navigates this complex landscape, its ability to adapt and innovate will be crucial for sustaining its market position and financial health moving forward [https://www.freedom969.com/business/pfizer-forecasts-2026-profit-below-expectations-on-lower-covid-product-sales, https://brusselsmorning.com/pfizer-forecasts-2026-profit-exclusive-insight-on-lower-covid-sales/85468].